Abstract: The invention relates to a new process for the purification of oligonucleotides which comprises the removal of the acid labile 5?hydroxy protecting group at the 5?-O-oligonucleotide terminus of the oligonucleotide by way of tangential flow filtration with an acidic buffer solution. The process requires less steps and allows a higher degree of automation.
Abstract: The present disclosure relates to a novel material and composition to perform purification and concentration of biological sample or nucleic acid in single step. The present disclosure also relates to a method to use of the same in two phase system to purify and concentrate the target biological materials and/or nucleic acids with an improved detection accuracy for diagnostics performance.
Abstract: Compositions are provided that have at least two of three active ingredients. The active ingredients maybe a salt having a cation N? C8-C16 alkanoyl-L di-basic amino acid —C1-C4 alkyl ester, a glycerol monoester of a fatty acid and a sugar ester of a fatty acid. The compositions are useful in methods of killing or inhibiting planktonic bacteria or fungi and bacteria or fungi embedded in a biofilm and prevention of biofilm formation on surfaces. The composition may further comprise a hydrogel and a benefit agent such as an antibiotic that can be solubilized by the hydrogel and supplied to the biofilm matrix by the active ingredients of the composition. Devices such as chronic wound coverings coated with the composition are also provided. Methods of preserving products with the composition are also provided.
Abstract: Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
Type:
Grant
Filed:
March 28, 2022
Date of Patent:
July 16, 2024
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Richard Kolesnick, Adriana Haimovitz-Friedman, Evis Sala, Zvi Fuks
Abstract: Provided is an oral composition, including the following components (A), (B), and (C): (A) non-polymer catechins; (B) rutin; and (C) astragalin, wherein a content of the component (A) in solids is from 2 mass % to 50 mass %, wherein a mass ratio between the component (A) and the component (B), [(B)/(A)], is from 0.05×10?2 to 50×10?2, and wherein a mass ratio between the component (A) and the component (C), [(C)/(A)], is from 1.0×10?3 to 50×10?3.
Abstract: A method of treating an infection of a lung in a patient in need thereof according to an embodiment includes administering to the patient an effective amount of a compound having the formula: or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 1, 2022
Date of Patent:
July 9, 2024
Assignee:
Lakewood Amedex, Inc.
Inventors:
Randolph B. Sleet, Steven A. Kates, Steven Parkinson
Abstract: The present disclosure provides a method for extracting a Lactarius hatsudake Tanaka polysaccharide compound, and relates to the field of active substance extraction.
Type:
Grant
Filed:
August 23, 2023
Date of Patent:
July 2, 2024
Assignee:
CENTRAL SOUTH UNIVERSITY OF
FORESTRY AND TECHNOLOGY
Abstract: The present disclosure provides methods of controlling the size of cellulose crystals by mixing a first composition comprising cellulose and coagulating this mixture with varying concentrations of hydrogen peroxide.
Type:
Grant
Filed:
March 31, 2021
Date of Patent:
June 25, 2024
Assignees:
Rutgers, The State University of New Jersey, Rowan University
Inventors:
David Salas de la Cruz, Xiao Hu, Stacy Love, David Verrill
Abstract: The present disclosure generally relates to compositions that inhibit matrix metalloproteinases (MMPs). These compositions may be particularly useful in treating oral cancer or an oropharyngeal cancer. The compositions can be prepared as a topical formulation, ointment, mouthwash, or packaged in a syringe.
Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.
Abstract: The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.
Abstract: Herein, we describe the development of non-?-lactam-based potentiator molecules that synergize with ?-lactam antibiotics and ?-lactam-?-lactamase inhibitor combinations against MDR/XDR P. aeruginosa phenotypes. The compound comprises a chemical structure or chemical formula of Formula (A) or a suitable salt form thereof, wherein “n” is a carbon tether having a length of between about 2-18 carbons.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
June 4, 2024
Assignee:
University of Manitoba
Inventors:
Frank Schweizer, Temilolu Idowu, Derek Ammeter
Abstract: In one aspect, TEMPO-cellulose structures and method of making the same are described herein. Briefly, a method of synthesizing TEMPO-cellulose comprises disposing cellulose in an aqueous medium, disposing first and second oxidizing agents in the aqueous medium and oxidizing hydroxyl groups of the cellulose via the first and second oxidizing agents in the presence of a 2,2,6,6-tetramethylpiperidine 1-oxyl radical (TEMPO) catalyst.
Type:
Grant
Filed:
July 30, 2018
Date of Patent:
May 14, 2024
Assignee:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Inventors:
John P. Moore, II, Jamie Hestekin, Peter Crooks, Narsimha Reddy Penthala, Shobanbabu Bommagani, Soma Shekar Dachavaram
Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
Abstract: A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patient's tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition.
Type:
Grant
Filed:
March 18, 2022
Date of Patent:
May 7, 2024
Assignee:
Medoderm Gmbh
Inventors:
Rivelino Montenegro, Thomas Freier, Karsten Henco
Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
April 30, 2024
Assignee:
Bristol-Myers Squibb Company
Inventors:
Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
Abstract: Embodiments of the present disclosure relate to materials and methods for preparing a clathrate-forming composition comprising a plurality of linear glucomonomer chains of about 15 to about 100 D-glucopyranosyl residues linked by ?-1,4 linkages, wherein the linear glucomonomer chains are a product of partial amylolysis of a modified starch substrate and wherein the product is flowable at temperatures within a range of 4-20° C. at about 20% w/v solids content. The present disclosure further describes methods of using the clathrate-forming compositions to form molecular dispersions or clathrates with hydrophobic guest molecules, kits for use in these methods, and molecular dispersions or clathrates obtained from the materials.
Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.
Abstract: It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
Type:
Grant
Filed:
November 21, 2022
Date of Patent:
March 26, 2024
Assignee:
GLYCOM A/S
Inventors:
Benjámin Podányi, Pierre Chassagne, Martin Matwiejuk, Markus Jondelius Hederos